The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Effect of antibiotic discontinuation strategies on mortality and infectious complications in critically ill septic patients: A meta-analysis and trial sequential analysis.
Abstract
Objective: To investigate methods of antibiotic duration minimization and their effect on mortality and infectious complications in critically ill patients. Data Sources: A systematic search of PubMed, Embase (via Ovid), clinicaltrials.gov, and the Cochrane Central Register of Controlled Trials (via Wiley) (CENTRAL, Issue 2, 2015). Study Selection: Randomized clinical trials comparing strategies to minimize antibiotic duration (days) for patients with infections or sepsis in intensive care. Data Extraction: A systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Dichotomous data are presented as relative risk (95% CIs) and p value, and continuous data are presented as mean difference (CI) and p value. Data Synthesis: We included 22 randomized clinical trials (6,046 patients). Strategies to minimize antibiotic use included procalcitonin (14 randomized clinical trials), clinical algorithms (two randomized clinical trials), and fixed-antibiotic duration (six randomized clinical trials). Procalcitonin (–1.23 [–1.61 to –0.85]; p < 0.001), but not clinical algorithm–guided antibiotic therapy (–7.41 [–18.18 to 3.37]; p = 0.18), was associated with shorter duration of antibiotic therapy. The intended reduction in antibiotic duration ranged from 3 to 7 days in fixed-duration antibiotic therapy randomized clinical trials. Neither procalcitonin-guided antibiotic treatment (0.91 [0.82–1.01]; p = 0.09), clinical algorithm–guided antibiotic treatment (0.67 [0.30–1.54]; p = 0.35), nor fixed-duration antibiotics (1.21 [0.90–1.63]; p = 0.20) were associated with reduction in mortality. Z-curve for trial sequential analyses of mortality associated with procalcitonin-guided therapy did not reach the trial sequential monitoring boundaries for benefit, harm, or futility (adjusted CI, 0.72–1.10). Trial sequential analyses for mortality associated with clinical algorithm and fixed-duration treatment accumulated less than 5% of the required information size. Despite shorter antibiotic duration, neither procalcitonin-guided therapy (0.93 [0.84–1.03]; p = 0.15) nor fixed-duration antibiotic therapy (1.06 [0.74–1.53]; p = 0.75) was associated with treatment failure. Conclusions: Although the duration of antibiotic therapy is reduced with procalcitonin-guided therapy or prespecified limited duration, meta-analysis and trial sequential analyses are inconclusive for mortality benefit. Data on clinical algorithms to guide antibiotic cessation are limited.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The undesirable effects of using procalcitonin along with clinical evaluation to decide when to discontinue antimicrobials are considered minimal, and do not outweigh the potential benefits [322].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [322]
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Estimating the mean and variance from the median, range, and the size of a sample
Hozo, S. P., Djulbegovic, B., & Hozo, I. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-13 · Cited by 9,062
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Self-citationChastre, J., Wolff, M., Fagon, J.-Y., Chevret, S., Thomas, F., Wermert, D., Clementi, E., Gonzalez, J., Jusserand, D., Asfar, P., et al. (2003) · JAMA · doi:10.1001/jama.290.19.2588 · Cited by 1,376
Bouadma, L., Luyt, C.-E., Tubach, F., Cracco, C., Alvarez, A., Schwebel, C., Schortgen, F., Lasocki, S., Veber, B., Dehoux, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61879-1 · Cited by 1,183
SINGH, N., ROGERS, P., ATWOOD, C. W., WAGENER, M. M., & YU, V. L. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.2.9909095 · Cited by 1,032
Brok, J., Thorlund, K., Wetterslev, J., & Gluud, C. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyn188 · Cited by 917
de Jong, E., van Oers, J. A., Beishuizen, A., Vos, P., Vermeijden, W. J., Haas, L. E., Loef, B. G., Dormans, T., van Melsen, G. C., Kluiters, Y. C., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00053-0 · Cited by 836
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
How to use biomarkers of infection or sepsis at the bedside: guide to clinicians
Póvoa, P., Coelho, L., Dal-Pizzol, F., Ferrer, R., Huttner, A., Conway Morris, A., Nobre, V., Ramirez, P., Rouze, A., Salluh, J., et al. (2023) · Intensive Care Medicine · doi:10.1007/s00134-022-06956-y · Cited by 292
Self-citationEstimating daily antibiotic harms: an umbrella review with individual study meta-analysis
Curran, J., Lo, J., Leung, V., Brown, K. A., Schwartz, K. L., Daneman, N., Garber, G. E., Wu, J. H., & Langford, B. J. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.022 · Cited by 150
O’Grady, N. P., Alexander, E., Alhazzani, W. A., Alshamsi, F. E., Cuellar‐Rodríguez, J., Jefferson, B. K., Kalil, A. C., Pastores, S. M., Patel, R., van Duin, D., et al. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000006022 · Cited by 95
Metadata
- Authors
- Arulkumaran, N., Khpal, M., Tam, K., Baheerathan, A., Corredor, C., & Singer, M.
- Affiliations
- University College London (GB)
- St Bartholomew's Hospital (GB)
- Venue
- Critical Care Medicine
- Published
- 2020-05
- Volume
- 48
- Issue
- 5
- Pages
- 757-764
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W3007553040
- Cited by
- 36
- References
- 47
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 10 · 2023: 4 · 2022: 4 · 2021: 4 · 2020: 4
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute for Health and Care Research (CL-2015-18-012, ACF-2016-21-021)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- sepsis, procalcitonin-guided antibiotic therapy, mortality, infectious complications, critically ill patients, intensive care, trial sequential analysis, Z-curve, futility, benefits, publication bias, risk of bias
- MeSH terms
- Procalcitonin, Algorithms, Anti-Bacterial Agents, Clinical Protocols, Drug Administration Schedule, Humans, Intensive Care Units, Protein Precursors, Biomarkers, Randomized Controlled Trials as Topic, Critical Illness, Sepsis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of antibiotic discontinuation strategies on mortality and infectious complications in critically ill septic patients: A meta-analysis and trial sequential analysis. https://app.cochat.ai/papers/10.1097/ccm.0000000000004267
- The paper
- Arulkumaran, N., Khpal, M., Tam, K., Baheerathan, A., Corredor, C., & Singer, M. (2020). Effect of antibiotic discontinuation strategies on mortality and infectious complications in critically ill septic patients: A meta-analysis and trial sequential analysis. Critical Care Medicine. https://doi.org/10.1097/ccm.0000000000004267
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.